Terms: = Leukemia AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E AND Clinical Outcome
106 results:
1. Patient-Specific Measurable Residual Disease Markers Predict outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
Tobiasson M; Pandzic T; Illman J; Nilsson L; Weström S; Ejerblad E; Olesen G; Björklund A; Olsnes Kittang A; Werlenius O; Lorentz F; Rasmussen B; Cammenga J; Weber D; Lindholm C; Wiggh J; Dimitriou M; Moen AE; Yip Lundström L; von Bahr L; Baltzer-Sollander K; Jädersten M; Kytölä S; Walldin G; Ljungman P; Groenbaek K; Mielke S; Jacobsen SEW; Ebeling F; Cavelier L; Smidstrup Friis L; Dybedal I; Hellström-Lindberg E
J Clin Oncol; 2024 Apr; 42(12):1378-1390. PubMed ID: 38232336
[TBL] [Abstract] [Full Text] [Related]
2. Cytidine deaminase status as a marker of response to azacytidine treatment in mds and AML patients.
Donnette M; Hamimed M; Ciccolini J; Sicard G; Correard F; Farnault L; Ouafik L; Venton G; Fanciullino R
Br J Haematol; 2023 Nov; 203(4):625-636. PubMed ID: 37691342
[TBL] [Abstract] [Full Text] [Related]
3. [Efficacy and safety of secondary allogeneic hematopoietic stem cell transplantation in 70 patients with recurrent hematologic malignancies after transplantation].
Han TT; Liu Y; Chen Y; Zhang YY; Fu HX; Yan CH; Mo XD; Wang FR; Wang JZ; Han W; Chen YY; Chen H; Sun YQ; Cheng YF; Wang Y; Zhang XH; Huang XJ; Xu LP
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):458-464. PubMed ID: 37550200
[No Abstract] [Full Text] [Related]
4. The clinical phenotype of germline RUNX1 mutations in relation to the accompanying somatic variants and RUNX1 isoform expression.
Cabrerizo Granados D; Barbosa I; Baliakas P; Hellström-Lindberg E; Lundin V
Genes Chromosomes Cancer; 2023 Nov; 62(11):672-677. PubMed ID: 37303296
[TBL] [Abstract] [Full Text] [Related]
5. LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome.
Kaastrup K; Gillberg L; Mikkelsen SU; Ørskov AD; Schöllkopf C; Mortensen BK; Porse B; Hansen JW; Grønbæk K
Clin Epigenetics; 2023 May; 15(1):91. PubMed ID: 37237325
[TBL] [Abstract] [Full Text] [Related]
6. The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non-AML myeloid neoplasms.
Kaseb H; Visconte V; Socha DS; Crane GM; Durkin L; Cook JR; Maciejewski JP; Hsi ED; Rogers HJ
Genes Chromosomes Cancer; 2023 Oct; 62(10):573-580. PubMed ID: 36959701
[TBL] [Abstract] [Full Text] [Related]
7. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Sauta E; Robin M; Bersanelli M; Travaglino E; Meggendorfer M; Zhao LP; Caballero Berrocal JC; Sala C; Maggioni G; Bernardi M; Di Grazia C; Vago L; Rivoli G; Borin L; D'Amico S; Tentori CA; Ubezio M; Campagna A; Russo A; Mannina D; Lanino L; Chiusolo P; Giaccone L; Voso MT; Riva M; Oliva EN; Zampini M; Riva E; Nibourel O; Bicchieri M; Bolli N; Rambaldi A; Passamonti F; Savevski V; Santoro A; Germing U; Kordasti S; Santini V; Diez-Campelo M; Sanz G; Sole F; Kern W; Platzbecker U; Ades L; Fenaux P; Haferlach T; Castellani G; Della Porta MG
J Clin Oncol; 2023 May; 41(15):2827-2842. PubMed ID: 36930857
[TBL] [Abstract] [Full Text] [Related]
8. PAK5 is a potential target in myelodysplastic syndrome through interacting with LMO2 and GATA1.
Pan X; Liu D; Ying M; Zheng G; Fan C; Pan F; Ke Q
Cell Mol Biol (Noisy-le-grand); 2022 Sep; 68(9):77-85. PubMed ID: 36905268
[TBL] [Abstract] [Full Text] [Related]
9. Molecular Drivers of Myelodysplastic Neoplasms (mds)-Classification and Prognostic Relevance.
Hoff FW; Madanat YF
Cells; 2023 Feb; 12(4):. PubMed ID: 36831294
[TBL] [Abstract] [Full Text] [Related]
10. Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes.
Konishi T; Sadato D; Toya T; Hirama C; Kishida Y; Nagata A; Yamada Y; Shingai N; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Okuyama Y; Harada H; Ohashi K; Harada Y; Doki N
Sci Rep; 2023 Feb; 13(1):2641. PubMed ID: 36788335
[TBL] [Abstract] [Full Text] [Related]
11. [The impact of donor-to-recipient gender compatibility on outcomes of haploid hematopoietic stem cell transplantation in patients with hematological malignancies].
Hu SS; Wu YB; Zhu PP; Shi JM; Yu J; Zhao YM; Lai XY; Liu LZ; Fu HR; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):992-1002. PubMed ID: 36709104
[No Abstract] [Full Text] [Related]
12. SF3B1 mutated mds: Blast count, genetic co-abnormalities and their impact on classification and prognosis.
Huber S; Haferlach T; Meggendorfer M; Hutter S; Hoermann G; Baer C; Kern W; Haferlach C
Leukemia; 2022 Dec; 36(12):2894-2902. PubMed ID: 36261576
[TBL] [Abstract] [Full Text] [Related]
13. The new diagnostic criteria for myelodysplasia-related acute myeloid leukemia is useful for predicting clinical outcome: comparison of the 4th and 5th World Health Organization classifications.
Park HS; Kim HK; Kim HS; Yang Y; Han HS; Lee KH; Son BR; Kwon J
Ann Hematol; 2022 Dec; 101(12):2645-2654. PubMed ID: 36220882
[TBL] [Abstract] [Full Text] [Related]
14. Isolated pancreatic myeloid sarcoma: A potential mimicker of pancreatic adenocarcinoma.
Soni A; Jindal S; Narang V; Singh A; Paul D; Kaur H
Indian J Pathol Microbiol; 2022; 65(3):676-678. PubMed ID: 35900500
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic role of controlling nutritional status score in hematological malignancies.
Zhang Y; Chen Q; Lu C; Yu L
Hematology; 2022 Dec; 27(1):653-658. PubMed ID: 35622088
[TBL] [Abstract] [Full Text] [Related]
16. In Vitro Generated Dendritic Cells of Leukemic Origin Predict Response to Allogeneic Stem Cell Transplantation in Patients With AML and mds.
Freudenreich M; Tischer J; Kroell T; Kremser A; Dreyßig J; Beibl C; Liepert A; Kolb HJ; Schmid C; Schmetzer H
J Immunother; 2022 Feb-Mar 01; 45(2):104-118. PubMed ID: 34864807
[TBL] [Abstract] [Full Text] [Related]
17. Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients - results of the PALG study 'PolAZA'.
Mądry K; Lis K; Tukiendorf A; Szwedyk P; Kapelko-Słowik K; Subocz E; Gołos A; Makowska W; Masternak A; Kopińska A; Czemerska M; Zawadzka-Leska S; Rusicka P; Drozd-Sokołowska J; Wiater E; Hołojda J; Pogłódek B; Centkowski P; Waszczuk-Gajda A; Machowicz R; Hałka J; Czerw T; Basak G; Dwilewicz-Trojaczek J
Hematology; 2021 Dec; 26(1):556-564. PubMed ID: 34384334
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic mutation constellations in acute myeloid leukaemia and myelodysplastic syndrome.
Iacobucci I; Mullighan CG
Curr Opin Hematol; 2021 Mar; 28(2):101-109. PubMed ID: 33427759
[TBL] [Abstract] [Full Text] [Related]
19. Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome.
Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Guo R; Tierens A; Minden MD; Chang H
Hum Pathol; 2020 Oct; 104():117-126. PubMed ID: 32798550
[TBL] [Abstract] [Full Text] [Related]
20. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-mds.
Kuendgen A; Nomdedeu M; Tuechler H; Garcia-Manero G; Komrokji RS; Sekeres MA; Della Porta MG; Cazzola M; DeZern AE; Roboz GJ; Steensma DP; Van de Loosdrecht AA; Schlenk RF; Grau J; Calvo X; Blum S; Pereira A; Valent P; Costa D; Giagounidis A; Xicoy B; Döhner H; Platzbecker U; Pedro C; Lübbert M; Oiartzabal I; Díez-Campelo M; Cedena MT; Machherndl-Spandl S; López-Pavía M; Baldus CD; Martinez-de-Sola M; Stauder R; Merchan B; List A; Ganster C; Schroeder T; Voso MT; Pfeilstöcker M; Sill H; Hildebrandt B; Esteve J; Nomdedeu B; Cobo F; Haas R; Sole F; Germing U; Greenberg PL; Haase D; Sanz G
Leukemia; 2021 Mar; 35(3):835-849. PubMed ID: 32595214
[TBL] [Abstract] [Full Text] [Related]
[Next]
